A study published in Nature Nanotechnology presents an innovative graphene-based neurotechnology with the potential to make a big impact in neuroscience and medical applications. The research is being developed for therapeutic applications through the spin-off INBRAIN Neuroelectronics.
The technology, called EGNITE, uses flexible, high-resolution, high-precision graphene-based implantable neurotechnology to record high-fidelity neural signals with exceptional clarity and precision. It also allows for highly targeted nerve modulation.
The technology was developed through a collaboration between the Catalan Institute of Nanoscience and Nanotechnology, the Universitat Autònoma de Barcelona, and other national and international partners. It has been patented and licensed to INBRAIN Neuroelectronics, which is leading the translation of the technology into clinical applications and products.
INBRAIN Neuroelectronics is gearing up for the first-in-human clinical trials of this innovative graphene technology and aims to continue advancing and maturing the technology for real therapeutic use.
The development of EGNITE electrodes has the capacity to place graphene at the forefront of neurotechnological materials, which would be a critical advancement in neuroelectronic therapeutics.
The research is led by ICN2 researchers Damià Viana, Steven T. Walston, and Eduard Masvidal-Codina and includes contributions from leading national and international institutions.
Overall, the article describes an innovative graphene-based neurotechnology that can have a transformative impact and continues to be researched for real therapeutic use.
>>Join our Facebook Group be part of community. <<